Wednesday, July 8, 2026

pharma · MASH · MASLD · SGMT

Sagimet Biosciences

Sagimet Biosciences clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

155 Bovet Rd, Suite 303, San Mateo, California 94402, US HQ
27 Employees
Public company Type
SGMT · NYSE Ticker
Company details
Status
Public
HQ
155 Bovet Rd, Suite 303, San Mateo, California 94402, US
Employees
27
Programs
12
Drugs
4
Patents
1
Intelligence · Clinical Programs

Sagimet Biosciences projects

6 ClinicalTrials.gov programs sponsored by Sagimet Biosciences.

Sagimet Biosciences has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Denifanstat

    Sagimet Biosciences

    Healthy

    phase 1 small molecule completed

    1 trial
  2. TVB-2640

    Sagimet Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule active

    1 trial
  3. TVB-2640

    Sagimet Biosciences

    Solid Malignant Tumor

    phase 1 small molecule completed

    1 trial
  4. TVB-2640 - 50 mg

    Sagimet Biosciences

    Non-alcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial
  5. TVB-3567

    Sagimet Biosciences

    Acne

    phase 1 small molecule active

    1 trial
  6. [14C]-TVB-2640

    Sagimet Biosciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Sagimet Biosciences have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.